Table 3.

Correlation between participant scores at baseline and 4 months

Association	Participants	n	Spearman’s ρ	95% CI around Spearman’s ρ
PHQ-9 at baseline and 4 months	All	63	0.42	0.19 to 0.61
	Intervention	33	0.37	0.04 to 0.64
	Control	30	0.71	0.47 to 0.85
GAD-7 at baseline and 4 months	All	62	0.40	0.17 to 0.59
	Intervention	32	0.40	0.07 to 0.66
	Control	30	0.51	0.18 to 0.73
WSAS at baseline and 4 months	All	62	0.52	0.31 to 0.68
	Intervention	32	0.45	0.12 to 0.69
	Control	30	0.76	0.55 to 0.88
MASA at baseline and 4 months	All	62	0.58	0.39 to 0.73
	Intervention	32	0.45	0.12 to 0.69
	Control	30	0.73	0.50 to 0.86
SF-36 PCS at baseline and 4 months	All	63	0.68	0.52 to 0.80
	Intervention	33	0.78	0.59 to 0.88
	Control	30	0.58	0.27 to 0.78
SF-36 MCS at baseline and 4 months	All	63	0.42	0.20 to 0.61
	Intervention	33	0.43	0.10 to 0.67
	Control	30	0.39	0.04 to 0.66

GAD-7, Generalised Anxiety Disorder Questionnaire 7; MASA, Morita Attitudinal Scale for Arugamama; MCS, Mental Component Score; PCS, Physical Component Score; PHQ-9, Patient Health Questionnaire 9; SF-36, Short Form 36 Health Survey Questionnaire; WSAS, Work and Social Adjustment Scale.